Issue 8, 2022

Activating the p53 anti-cancer pathway by targeting the MDM2/MDMX dimer interface with short peptide segments: a computational peptide design experiment

Abstract

Formation of the MDM2/MDMX heterodimer through association of the RING domains of the MDM2 and MDMX proteins is essential for p53 activation. Disrupting the formation of this heterodimer is, therefore, a promising approach for p53 reactivation therapy. Here, we use blind docking simulations of dodecapeptide segments to the MDM2 RING domain, in order to assess their potential to disrupt the MDM2/MDMX formation. We used the KEIQLVIKVFI489A and KEIQLVIKVAE489A dodecapeptides as reference and control peptides since the former is reported to activate the p53 pathway through reducing p53 ubiquitination, while the latter has no effect on p53 ubiquitination. We could rationalize the difference between the activities of the two peptides in terms of preferential binding (ΔΔG) to the MDM2/MDMX interface hotspot residues compared to binding to sites outside the interface region. Binding of the KEIQLVIKVFI489A reference peptide to the MDM2/MDMX interface region was found to be more stable, ΔG = −3.95 kcal mol−1, than its binding to the outside of the interface, ΔG= −2.93 kcal mol−1, indicating preferential binding (ΔΔG = −1.02 kcal mol−1) of the KEIQLVIKVFI489A reference peptide to the MDM2/MDMX interface. By contrast, binding of the KEIQLVIKVAE489A control peptide to the MDM2/MDMX interface region is less stable, ΔG = −1.50 kcal mol−1, than its binding to the outside of the interface, ΔG = −2.29 kcal mol−1, indicating preferential binding to sites outside the interface region (ΔΔG = +0.79 kcal mol−1). Preferential binding (ΔΔG) could, therefore, be a better metric for the design and identification of new peptide leads. Systematic mutation of the I485 and I489 residues of the reference peptide leads to identification of 14 mutant peptides that show at least three-fold preferential binding to the MDM2/MDMX interface (ΔΔG ∼ −3.00 kcal mol−1) lower than the KEIQLVIKVFI489A reference peptide (ΔΔG = −1.02 kcal mol−1), with the KEIQLVSKVFI489M mutant being the most stable (ΔΔG = −3.96 kcal mol−1). These peptides could, therefore, provide lead structures for p53 reactivation therapy.

Graphical abstract: Activating the p53 anti-cancer pathway by targeting the MDM2/MDMX dimer interface with short peptide segments: a computational peptide design experiment

Article information

Article type
Paper
Submitted
16 Mar 2022
Accepted
10 May 2022
First published
26 May 2022

Mol. Syst. Des. Eng., 2022,7, 996-1006

Activating the p53 anti-cancer pathway by targeting the MDM2/MDMX dimer interface with short peptide segments: a computational peptide design experiment

K. M. ElSawy, F. M. Alminderej, C. S. Verma and L. S. D. Caves, Mol. Syst. Des. Eng., 2022, 7, 996 DOI: 10.1039/D2ME00042C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements